These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 1712662)

  • 1. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
    McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
    Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
    McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
    Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
    Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
    J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
    Waits TM; Greco FA; Greer JP; Hainsworth JD
    Leuk Lymphoma; 1993 Aug; 10(6):453-9. PubMed ID: 7691308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy.
    McMaster ML; Greer JP; Greco FA; Johnson DH; Wolff SN; Hainsworth JD
    J Clin Oncol; 1991 Jun; 9(6):941-6. PubMed ID: 1709685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
    J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate and high grade malignant non-Hodgkin's lymphomas: preliminary results using a new combination regimen (EVE-COPEM).
    Battista C; Panza N; Chiurazzi B; Iodice G; Esposito G; Cocorocchio E; Bevilacqua N; Pacilio G
    Biomed Pharmacother; 1993; 47(4):145-54. PubMed ID: 8018826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
    J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
    Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
    Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
    Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
    Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
    J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
    Ibrahim EM; Satti MB; Al-Idrissi HY; Al-Mulhim FA; Abssod GH; Abdel Jabar A
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):391-401. PubMed ID: 2454821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
    Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
    J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.